The Biden Administration's proposal to reclassify cannabis from a Schedule I drug to Schedule III has encountered a roadblock as reports emerged indicating that the DEA's Administrator, Anne Milgram, did not sign the anticipated rescheduling order. This move was seen as a crucial step towards acknowledging the medical benefits of cannabis and positioning it in a category with reduced potential for abuse, a departure from its current classification alongside heroin and LSD.
Expectations were high for the DEA to push forward with the reclassification plan this week, which would have marked a significant shift in the federal government's stance on cannabis. However, recent developments suggest that the proposal has hit a standstill, causing uncertainty and disappointment among those in the cannabis industry and advocates for reform. The delay in signing the rescheduling order has led to speculation and concerns about the future of cannabis regulation under the Biden Administration, especially in light of the positive momentum that had been building around the potential reclassification.